The Clinical Implications of The Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide In The CARD Trial - William Oh and Stephen Freedland
Stephen Freedland
William Oh and Stephen Freedland join Alicia Morgans to discuss the efficacy and safety in older patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide an analysis of the CARD Trial.
The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin
Mary-Ellen Taplin
Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study.